… Considering that early treatment initiation has the potential to prevent disease progression,
molnupiravir (MOV) and nirmatrelvir/ritonavir (NMV/r) were developed as oral antiviral agents…

… We performed a retrospective territory-wide observational study evaluating the safety and
efficacy of nirmatrelvir-ritonavir when compared with molnupiravir in the treatment of patients …

… trial to evaluate the efficacy and safety of treatment with molnupiravir started within 5 days
… 800 mg of molnupiravir or placebo twice daily for 5 days. The primary efficacy end point was …

… the findings of six trials of molnupiravir compared with either standard of care or placebo.
These reviews suggested that molnupiravir reduces the frequency of hospital admissions in …

… AGILE is a Phase Ib/IIa platform for rapidly evaluating COVID-19 treatments. In this trial (NCT04746183)
we evaluated the safety and optimal dose of molnupiravir in participants with …

… ) that was planned to assess efficacy and safety of molnupiravir in 1433 non-hospitalized …
by the independent data safety monitoring board due to excessive benefit in molnupiravir arm …

… Within the case-control study design, patients with COVID-19 received molnupiravir or
nirmatrelvir plus ritonavir treatment in the outpatient setting before the reference date, which was …

… Below, we report our experience in the use of molnupiravir, the first … in the treatment of
patients with COVID-19. The aim of the study is to verify the efficacy and tolerability of molnupiravir …

… the efficacy and safety of nirmatrelvir/ritonavir (Paxlovid) with molnupiravir in the treatment of
… a significant difference between nirmatrelvir/ritonavir and molnupiravir in terms of all-cause …

… Objective: To determine the effectiveness of nirmatrelvir/ritonavir and molnupiravir among …
of nirmatrelvir/ritonavir or molnupiravir compared to no antiviral drug treatment for COVID-19 in …